Company intelligence / Profile preview

Learmont Pharmaceuticals

New York, New York, United Stateslearmontpharmaceuticals.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Learmont Pharmaceuticals is developing LORAZOL, a repurposed combination of monobenzone and imiquimod that has shown efficacy in treating late-stage melanoma. The drug received Orphan Drug Designation from the FDA in 2019 for the treatment of stage IIB-IV melanoma. A confirmatory Phase 2 study was planned to begin in 2020.

Therapeutic areas: Oncology
Modalities: Small molecules (repurposed drug combinations)
Industry: Biotech

Drug pipeline

6 assets

LORAZOL

Preclinical

5 more assets in the full pipeline.

Beyond the preview

Go deeper on Learmont Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Learmont Pharmaceuticals.